THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Kenichi Tanaka to Recombinant Proteins

This is a "connection" page, showing publications Kenichi Tanaka has written about Recombinant Proteins.
Connection Strength

1.662
  1. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. Anesth Analg. 2008 Mar; 106(3):719-24, table of contents.
    View in: PubMed
    Score: 0.274
  2. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg. 2008 Mar; 106(3):732-8, table of contents.
    View in: PubMed
    Score: 0.274
  3. Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy. Anesth Analg. 2019 08; 129(2):339-345.
    View in: PubMed
    Score: 0.151
  4. Coagulation Management During Liver Transplantation: Use of Fibrinogen Concentrate, Recombinant Activated Factor VII, Prothrombin Complex Concentrate, and Antifibrinolytics. Semin Cardiothorac Vasc Anesth. 2018 Jun; 22(2):164-173.
    View in: PubMed
    Score: 0.134
  5. Assessment of Fibrin Polymerization During Bivalirudin Anticoagulation for Transcatheter Aortic Valve Replacement. J Cardiothorac Vasc Anesth. 2017 08; 31(4):e65-e66.
    View in: PubMed
    Score: 0.127
  6. Three-factor prothrombin complex concentrate and hemostasis after high-risk cardiovascular surgery. Transfusion. 2013 Apr; 53(4):920-1.
    View in: PubMed
    Score: 0.097
  7. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. J Trauma. 2010 May; 68(5):1151-7.
    View in: PubMed
    Score: 0.080
  8. Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth. 2010 Dec; 24(6):959-63.
    View in: PubMed
    Score: 0.079
  9. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost. 2009 May; 101(5):827-33.
    View in: PubMed
    Score: 0.074
  10. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2008 Jan; 19(1):106-8.
    View in: PubMed
    Score: 0.068
  11. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res. 2008; 122(1):117-23.
    View in: PubMed
    Score: 0.067
  12. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anesth Analg. 2007 Oct; 105(4):933-9, table of contents.
    View in: PubMed
    Score: 0.066
  13. Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. Anesth Analg. 2007 Apr; 104(4):763-5.
    View in: PubMed
    Score: 0.064
  14. Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb Res. 2004; 113(5):333-9.
    View in: PubMed
    Score: 0.051
  15. Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation. Ann Card Anaesth. 2016 Jul-Sep; 19(3):418-24.
    View in: PubMed
    Score: 0.030
  16. In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. Thromb Res. 2013 Jul; 132(1):106-11.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES